Novel quinazoline-triazole-based <i>N</i>-hydroxybenzamides/<i>N</i>-hydroxypropenamides as HDAC inhibitors: design, synthesis, biological evaluation, and docking studies.

RSC Adv · 2025 · PMC12282580 · PMID 40697461

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

A notable trend was observed when comparing 6-halogenated and 7-halogenated derivatives: 7-Br (7h, 11h) exhibited stronger anticancer activity than 6-Br (7g, 11g), whereas the 6-F derivative (7e, 11e) was more potent than the 7-F derivative (7f, 11f).

also in 2,325 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Novel quinazoline-triazole-based &lt;i&gt;N&lt;/i&gt;-hydroxybenzamides/&lt;i&gt;N&lt;/i&gt;-hydroxypropenamides as HDAC inhibitors: design, synthesis, biological evaluation, and docking studies.

The sentences

Novel quinazoline-triazole-based <i>N</i>-hydroxybenzamides/<i>N</i>-hydroxypropenamides as HDAC inhibitors: design, synthesis, biological evaluation, and docking studies.